<DOC>
	<DOCNO>NCT01116141</DOCNO>
	<brief_summary>The purpose study determine CH-4051 safe effective treatment rheumatoid arthritis .</brief_summary>
	<brief_title>A Study CH-4051 Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>Multi-center , multi-national , double-blind , randomize , active-controlled ( MTX ) , 3-month study 4 dos CH-4051 ( 0.3 mg , 1.0 mg , 3.0 mg 3.0 mg 1mg folic acid supplementation p.o . daily ) compare `` standard '' dose MTX 20 mg per week 1 mg folic acid supplementation p.o . daily . This study conduct two part : Part A : Patients randomize 0.3 mg CH-4051 , 1.0 mg CH-4051 MTX . Part B : Patients randomize Part B Data Monitoring Committee review safety data Part A approximately 25 patient ( 10 patient CH-4051 dose group 5 patient MTX group ) complete 3 month treatment . At time DMC make recommendation whether commence randomization 3.0 mg CH-4051 , 3.0 mg CH-4051 1.0 mg folic acid .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Patients must age 18 80 ; Have diagnose active rheumatoid arthritis accord ACR criterion functional class IIII ; Have least 6 swollen joint ( max = 66 ) 6 tender joint ( max = 68 ) screen baseline visit ; Patients must least one follow : Creactive protein &gt; 1.0 mg/dl screening ; erythrocyte sedimentation rate &gt; 28 mm/Hr ; Patients must take methotrexate 15 25 mg/week least 3 month stable dose least 6 week ; Patients must either Rheumatoid Factor ( RF ) anticyclic citrullinated peptide ( antiCCP ) positive ; Patients must voluntarily sign informed consent . Patients receive previous therapy biologic agent ; Patients currently take disease modify antirheumatic drug ( DMARD ) MTX ; Previous nonbiologic DMARD therapy permit long last dose least 30 day prior baseline ; Female patient child bear potential pregnant use two method contraception ( least one barrier : i.e . condom ) partner ; Male patient sexually active use two method contraception ( least one barrier : i.e . condom ) partner ; Patients current active infection infection require IV drug therapy within 30 day baseline oral therapy within 15 day Baseline ; Patients surgical procedure within 30 day baseline ; Patients history HIV ; Patients Hepatitis B surface antigen positive and/or Hepatitis C antibody positive ; Patients consume 4 unit alcohol per week ( 1 unit = 5 ounces/150 ml wine = 1.5 ounces/45 ml spirit = 12 ounces/360 ml beer ) ; Patients currently receive investigational drug receive investigational drug within 30 day baseline 5 halflives investigational drug ( whichever longer ) ; Patients history cancer within past 5 year successfully treat , nonmetastatic cutaneous squamous cell basal cell carcinoma cervical cancer situ ; Patients history , , disease associate inflammatory arthritis RA ; Patients pulmonary fibrosis ( Chest xray must take within 28 day screen ) ; Patients receive probenecid ; Patients receive steroid injection within 30 day baseline ; Patients concomitant disease unstable ( i.e . cardiac , pulmonary ) may affect drug activity ( i.e . absorption , reaction , change kinetics ) ; Patients , investigator 's opinion , significant renal hepatic impairment ; Patients serum creatinine level &gt; 1.5 mg/dl screening ; Patients ALT &gt; 1.5 ULN screening ; Patients consider investigator unsuitable candidate receive CH4051 ; Wheelchair bedbound patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>MTX</keyword>
	<keyword>CH-405</keyword>
	<keyword>antifolates</keyword>
</DOC>